Atorvastatin with Lactobacillus rhamnosus supplementation Ameliorates Pathogenesis of High fat-High fructose diet induced non-alcoholic fatty liver disease in rats

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a broad term that includes anything from simple adipose tissue deposition in the liver to more advanced steatosis with concomitant hepatitis, fibrosis, and cirrhosis. The incidence of NAFLD is predicted to rise because of the increased prevalence of related disorders such as obesity and type 2 diabetes mellitus (T2DM). All statins seem to be successful in decreasing patients' cholesterol levels with NAFLD, while there is greater experience with atorvastatin, the only statin that has been shown to reduce the risk of cardiovascular events in these individuals. Atorvastatin, like other statins, acts by blocking HMG-CoA reductase, an enzyme located in liver tissue that is important in the production of cholesterol in the body. But Atorvastatin's primary adverse impact is a loss of muscle and an accelerated breakdown of muscular tissue (rhabdomyolysis). Certain probiotic lactobacilli strains offer positive benefits, most likely via anti-inflammatory activities and intestinal barrier stability, which reduces liver diseases. The present study's goal is to see how Atorvastatin at a subtherapeutic dosage combined with a probiotic strain, Lactobacillus rhamnosus, affects male SD rats in the treatment of NAFLD.